In February, we added 94 citations in DIDB, including 38 in vitro (with 16 articles published in February 2023) and 56 in vivo articles (with 38 articles published in February 2023).
Seven recently approved NDAs and BLAs were also added: anacaulase (NEXOBRID), bexagliflozin (BRENZVVY), lecanemab (LEQEMBI), lenacapavir (SUNLENCA), mosunetuzumab (LUNSUMIO), ublituximab (BRIUMVI), xenon Xe-129 hyperpolarized (XENOVIEW).
You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.
As always, feel free to contact us if you have any questions or comments.